X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (37477) 37477
Publication (1940) 1940
Book Review (444) 444
Book Chapter (207) 207
Newsletter (198) 198
Magazine Article (164) 164
Conference Proceeding (54) 54
Newspaper Article (50) 50
Book / eBook (40) 40
Trade Publication Article (18) 18
Dissertation (16) 16
Web Resource (13) 13
Paper (6) 6
Reference (2) 2
Data Set (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30928) 30928
heparin - therapeutic use (16551) 16551
female (14448) 14448
male (13526) 13526
anticoagulants - therapeutic use (10831) 10831
heparin (9909) 9909
index medicus (9795) 9795
middle aged (9339) 9339
adult (7861) 7861
aged (7616) 7616
animals (5498) 5498
heparin, low-molecular-weight - therapeutic use (4890) 4890
molecular-weight heparin (4843) 4843
hematology (4700) 4700
anticoagulants (4652) 4652
peripheral vascular disease (4120) 4120
heparin - administration & dosage (3948) 3948
treatment outcome (3861) 3861
heparin - adverse effects (3767) 3767
risk factors (3725) 3725
fibrinolytic agents - therapeutic use (3688) 3688
thrombosis (3660) 3660
anticoagulants - adverse effects (3441) 3441
surgery (3263) 3263
cardiac & cardiovascular systems (3112) 3112
anticoagulants - administration & dosage (2891) 2891
venous thromboembolism (2728) 2728
pregnancy (2703) 2703
unfractionated heparin (2640) 2640
pharmacology & pharmacy (2596) 2596
thromboembolism (2594) 2594
time factors (2592) 2592
prevention (2571) 2571
medicine, general & internal (2445) 2445
deep-vein thrombosis (2278) 2278
aged, 80 and over (2098) 2098
heparin - pharmacology (2075) 2075
prospective studies (2061) 2061
thromboembolism - prevention & control (2028) 2028
retrospective studies (2022) 2022
therapy (1997) 1997
postoperative complications - prevention & control (1942) 1942
anticoagulation (1932) 1932
warfarin - therapeutic use (1927) 1927
adolescent (1909) 1909
aspirin - therapeutic use (1851) 1851
thrombocytopenia - chemically induced (1782) 1782
thrombosis - prevention & control (1702) 1702
drug therapy, combination (1692) 1692
care and treatment (1690) 1690
hemorrhage - chemically induced (1688) 1688
thrombosis - drug therapy (1634) 1634
platelet aggregation inhibitors - therapeutic use (1621) 1621
thrombolytic therapy (1592) 1592
pulmonary embolism - drug therapy (1589) 1589
enoxaparin (1587) 1587
analysis (1561) 1561
glycosaminoglycans (1558) 1558
risk (1528) 1528
venous thrombosis - drug therapy (1528) 1528
myocardial infarction - drug therapy (1521) 1521
venous thrombosis (1514) 1514
drug therapy (1496) 1496
health aspects (1493) 1493
rats (1491) 1491
warfarin (1485) 1485
dose-response relationship, drug (1435) 1435
medicine & public health (1430) 1430
management (1404) 1404
acute disease (1401) 1401
venous thrombosis - prevention & control (1396) 1396
blood coagulation - drug effects (1364) 1364
recurrence (1359) 1359
follow-up studies (1357) 1357
pulmonary embolism (1350) 1350
child (1320) 1320
heparin-induced thrombocytopenia (1311) 1311
cancer (1273) 1273
research (1264) 1264
clinical trials as topic (1257) 1257
partial thromboplastin time (1242) 1242
pulmonary-embolism (1241) 1241
pulmonary embolism - prevention & control (1237) 1237
prophylaxis (1235) 1235
blood coagulation tests (1226) 1226
anticoagulants - pharmacology (1223) 1223
recombinant proteins - therapeutic use (1207) 1207
thrombophlebitis - drug therapy (1207) 1207
mice (1178) 1178
aspirin (1168) 1168
heparin, low-molecular-weight - administration & dosage (1163) 1163
thrombosis - etiology (1161) 1161
diagnosis (1134) 1134
venous thromboembolism - prevention & control (1130) 1130
abridged index medicus (1126) 1126
heparin, low-molecular-weight - adverse effects (1118) 1118
complications (1117) 1117
thrombophlebitis - prevention & control (1074) 1074
mortality (1067) 1067
randomized controlled trials as topic (1055) 1055
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (31) 31
Online Resources - Online (14) 14
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Pharmacy (1) 1
Credit Valley Hospital - Closed Orders (1) 1
Gerstein Science - Pharmacy (1) 1
Gerstein Science - Theses (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Online (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
University Archives - Archives (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (32339) 32339
German (1640) 1640
French (1389) 1389
Russian (714) 714
Spanish (439) 439
Italian (374) 374
Japanese (252) 252
Polish (201) 201
Chinese (159) 159
Dutch (63) 63
Danish (62) 62
Hungarian (56) 56
Czech (54) 54
Portuguese (54) 54
Romanian (54) 54
Bulgarian (39) 39
Swedish (37) 37
Norwegian (32) 32
Ukrainian (28) 28
Finnish (26) 26
Croatian (22) 22
Slovak (20) 20
Hebrew (18) 18
Serbian (17) 17
Turkish (17) 17
Korean (6) 6
Afrikaans (5) 5
Lithuanian (5) 5
Bosnian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and Haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Summary Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct... 
Review Article | Rivaroxaban | Antidotes | Dabigatran | New anticoagulants | Apixaban | ANDEXANET-ALPHA | VITAMIN-K ANTAGONISTS | rivaroxaban | apixaban | ATRIAL-FIBRILLATION | antidotes | IN-VITRO | ANTIIDIOTYPIC ANTIBODIES | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | dabigatran | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thrombosis - complications | Humans | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Vitamin K - antagonists & inhibitors | Benzamides - therapeutic use | Anticoagulants - chemistry | Factor Xa - therapeutic use | Intracranial Hemorrhages - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Hemostatics - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Infusions, Parenteral | Clinical Trials as Topic | Factor Xa Inhibitors - therapeutic use | Animals | Protamines - therapeutic use | Pyridones - therapeutic use | Thrombosis - drug therapy | Hemorrhage - chemically induced | Hemostatics - therapeutic use
Journal Article
Current Opinion in Pharmacology, ISSN 1471-4892, 06/2018, Volume 40, pp. 39 - 45
Journal Article
Current Drug Discovery Technologies, ISSN 1570-1638, 12/2009, Volume 6, Issue 4, pp. 281 - 289
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Circulation, ISSN 0009-7322, 07/2007, Volume 116, Issue 5, pp. 552 - 560
fondaparinux | CARDIAC & CARDIOVASCULAR SYSTEMS | bivalirudin | STROKE PREVENTION | myocardial infarction | INITIAL TREATMENT | heparin | ST-ELEVATION | PERCUTANEOUS CORONARY INTERVENTION | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | anticoagulants | mortality | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | enoxaparin | NONVALVULAR ATRIAL-FIBRILLATION | Fibrinolytic Agents - classification | Recombinant Proteins - therapeutic use | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Benzylamines - adverse effects | Factor Xa Inhibitors | Anticoagulants - classification | Humans | Thrombin - antagonists & inhibitors | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Rivaroxaban | Pyridines - adverse effects | Angina, Unstable - drug therapy | Prothrombin - antagonists & inhibitors | Hirudins - pharmacokinetics | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Polysaccharides - therapeutic use | Azetidines - adverse effects | Peptide Fragments - pharmacokinetics | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Forecasting | Azetidines - therapeutic use | Brain Ischemia - drug therapy | Peptide Fragments - therapeutic use | Benzylamines - pharmacokinetics | Hemorrhage - chemically induced | Heparin - therapeutic use | Recombinant Proteins - pharmacokinetics | Dabigatran | Fibrinolytic Agents - pharmacokinetics | Fibrinolytic Agents - therapeutic use | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Thrombophilia - drug therapy | Pyridines - therapeutic use | Azetidines - pharmacokinetics | Clinical Trials as Topic | Coumarins - therapeutic use | Polysaccharides - pharmacology | Thiophenes - pharmacokinetics | Myocardial Infarction - drug therapy | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Benzylamines - therapeutic use | Physiological aspects | Usage | Warfarin | Heparin
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 7, p. CD006650
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
Mortality and morbidity in acute coronary syndromes (ACSs), caused principally by plaque erosion or rupture leading to thrombus formation and myocardial... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
by Büller, Harry R and Prins, Martin H and Lensin, Anthonie W. A and Decousus, Hervé and Jacobson, Barry F and Minar, Erich and Chlumsky, Jaromir and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Cohen, Alexander and Berkowitz, Scott D and Bounameaux, Henri and Davidson, Bruce L and Misselwitz, Frank and Gallus, Alex S and Raskob, Gary E and Schellong, Sebastian and Segers, Annelise and Berkowitz, Scott and Gallus, Alexander and Lensing, Anthonie W. A and Haskell, Lloyd and Raskob, Gary and Bauersachs, Rupert and van Bellen, Bonno and Boda, Zoltán and Borris, Lars and Brenner, Benjamin and Brighton, Tim and Davidson, Bruce and Decousus, Herve and Eriksson, Henry and Jacobson, Barry and Kakkar, Ajay and Kwong, Yok-Lam and Lee, Lai Heng and Meijer, Karina and van der Meer, Jan and Monreal, Manuel and Piovella, Franco and Sandset, Per Morten and Smith, Mark and Tomkowski, Witold and Wang, Yuqi and Brandjes, Dees and Mac Gillavry, Melvin and Otten, Hans-Martin and Carlsson, Anders and Laporte, Silvy and Schulman, Sam and Gent, Michael and Turpie, Alexander and Martinelli, Ida and Lensing, Anthonie W and Muhlhofer, Eva and Tewes, Miriam and Trajanovic, Mila and Muller, Karin and Kim, Calvin and Gebel, Martin and Benson, Alice and Pap, Akos Ferenc and Goie, Juliette and Horvat-Broecker, Anea and Spadari, Giovanni and Peters-Wulf, Cornelia and Roig, J and Baker, R and Bianchi, A and Blombery, P and Brighton, T and Campbell, P and Carroll, P and Geraghty, R and Chong, B and Ramanathan, S and Archis, C and Coughlin, P and Salem, H and Crispin, P and Dean, M and Soni, R and Denaro, C and Kubler, P and Coghlan, D and Gallus, A and Gan, T. Eng and Tran, H and Coleman, C and Jackson, D and Khalafallah, A and Leahy, M and Leyden, M and Leyden, D and Sturtz, C and McCann, A and Gibbs, H and McRae, S and Richards, B and ... and The EINSTEIN–PE Investigators and EINSTEIN-PE Investigators and EINSTEIN–PE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article